ReviewIndian journal of endocrinology and metabolism
Growth Outcomes and Safety of Recombinant Growth Hormone in Noonan Syndrome: A Systematic Review and Meta-Analysis.
Review in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Noonan syndrome (NS), a RASopathy marked by partial resistance within the GH-IGF-1 axis, is characterised by short stature. Although growth hormone is commonly prescribed, there is a gap in data on long-term efficacy and safety profile. The objective of this study was to assess the long-term growth response and safety profile of recombinant human growth hormone (rhGH) therapy in children with NS. Randomised and observational studies reporting height outcomes in children with NS treated with rhGH were included. Thirty-nine studies, including 3167 patients, were analysed. At baseline, children had marked growth impairment [mean height standard deviation score (SDS) -2.95]. After 1 year of therapy, height SDS increased significantly (mean change +1.16). rhGH therapy leads to meaningful and sustained improvements in linear growth in children with NS without major safety concerns. Early initiation and continuation of therapy, alongside regular cardiac monitoring, should be considered in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.